Key points from article :
Generate:Biomedicines has teamed up with Roswell Park Comprehensive Cancer Center to develop new AI-powered chimeric antigen receptor (CAR) T-cell therapies for cancer. The collaboration aims to create engineered T-cell treatments targeting ovarian cancer and other solid tumors, leveraging generative artificial intelligence.
The partnership combines Generate:Biomedicines' AI-driven drug discovery with Roswell Park’s expertise in cell therapy design, clinical trials, and manufacturing. Together, they will co-develop and optimize advanced cell therapies, sharing research, development, and commercialization costs and profits. Roswell Park will also host Phase I and II clinical trials and recommend lead investigators.
This initiative aligns with New York State’s $98 million investment in a new cell and gene therapy hub at Roswell Park, set to become the largest academic cell therapy center in the U.S. The collaboration is expected to accelerate breakthroughs in personalized cancer treatments, further advancing AI-driven medical innovations.
